Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis

被引:39
作者
Butterfield, Joseph H. [1 ]
Ravi, Anupama [2 ]
Pongdee, Thanai [1 ]
机构
[1] Mayo Clin, Div Allerg Dis, 200 Southwest 1st St, Rochester, MN 55902 USA
[2] Mayo Clin, Div Pediat Allergy & Immunol, 200 1st St Southwest, Rochester, MN 55905 USA
关键词
N-methylhistamine; 23dinor-11 beta Prostaglandin(PG) F2 alpha; Leukotriene(LT) E4; Tryptase; Histamine; Neuropeptide; INDOLENT SYSTEMIC MASTOCYTOSIS; BONE-MARROW; TRYPTASE LEVELS; HUMAN-LUNG; PROSTAGLANDIN D-2; SERUM-LEVELS; ACTIVATION; HISTAMINE; DISEASE; PLASMA;
D O I
10.1016/j.iac.2018.04.011
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Mast cells leave evidence, a "fingerprint," of their participation in acute and chronic clinical events. That fingerprint is an elevation, either chronic or acute, in levels of their secreted mediators or their metabolites. Of these, only serum tryptase is currently one of the diagnostic criteria for systemic mastocytosis or mast cell activation. Combinations of easily obtained and quantified urinary mast cell mediator metabolite levels correlate well with bone marrow findings of systemic mastocytosis. By inhibiting synthesis of or blockading receptors to the elevated mast cell mediator, relief of clinical symptoms can often be achieved.
引用
收藏
页码:397 / +
页数:15
相关论文
共 68 条
[1]   PEROXIDASE-ACTIVITY IN MAST-CELL GRANULES IN URTICARIA PIGMENTOSA [J].
AKIYAMA, M ;
WATANABE, Y ;
NISHIKAWA, T .
DERMATOLOGICA, 1989, 178 (03) :145-150
[2]   IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis [J].
Brockow, K ;
Akin, C ;
Huber, M ;
Metcalfe, DD .
CLINICAL IMMUNOLOGY, 2005, 115 (02) :216-223
[3]   Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase [J].
Brockow, K ;
Akin, C ;
Huber, M ;
Scott, LM ;
Schwartz, LB ;
Metcalfe, DD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) :82-88
[4]   Increased leukotriene E4 excretion in systemic mastocytosis [J].
Butterfield, Joseph H. .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2010, 92 (1-4) :73-76
[5]   Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis [J].
Carter, Melody C. ;
Clayton, Sarah T. ;
Komarow, Hirsh D. ;
Brittain, Erica H. ;
Scott, Linda M. ;
Cantave, Daly ;
Gaskins, Donna M. ;
Maric, Irina ;
Metcalfe, Dean D. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 136 (06) :1673-U378
[6]   A French National Survey on Clotting Disorders in Mastocytosis [J].
Carvalhosa, Ana B. ;
Aouba, Achille ;
Damaj, Gandhi ;
Canioni, Danielle ;
Brouzes, Chantal ;
Gyan, Emmanuel ;
Durupt, Stephane ;
Durieu, Isabelle ;
Cathebras, Pascal ;
Costedoat-Chalumeau, Nathalie ;
Launay, David ;
Pilmis, Benoit ;
Barete, Stephane ;
Frenzel, Laurent ;
Lortholary, Olivier ;
Hermine, Olivier ;
Hermans, Cedric ;
Chandesris, Marie-Olivia .
MEDICINE, 2015, 94 (40)
[7]  
CASTELLS MC, 1987, J IMMUNOL, V138, P2184
[8]   Prostaglandin D-2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis [J].
Cho, Catherine ;
Anna Nguyen ;
Bryant, Katherine J. ;
O'Neill, Sean G. ;
McNeil, H. Patrick .
IMMUNITY INFLAMMATION AND DISEASE, 2016, 4 (01) :64-69
[9]   Signaling by IL-31 and functional consequences [J].
Cornelissen, Christian ;
Luescher-Firzlaff, Juliane ;
Baron, Jens Malte ;
Luescher, Bernhard .
EUROPEAN JOURNAL OF CELL BIOLOGY, 2012, 91 (6-7) :552-566
[10]  
de Paulis A, 1999, J IMMUNOL, V163, P2799